US 11,672,792 B2
Topical formulations comprising montelukast and combinations with mussel adhesive proteins
Bengt Ingemar Samuelsson, Stockholm (SE); and Ming Gu, Jiangyin (CN)
Assigned to ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD, Shanghai (CN)
Appl. No. 16/628,170
Filed by ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD, Shanghai (CN)
PCT Filed Jul. 4, 2018, PCT No. PCT/CN2018/094441
§ 371(c)(1), (2) Date Jan. 2, 2020,
PCT Pub. No. WO2019/007356, PCT Pub. Date Jan. 10, 2019.
Claims priority of application No. PCT/CN2017/091819 (WO), filed on Jul. 5, 2017; and application No. PCT/CN2018/087058 (WO), filed on May 16, 2018.
Prior Publication US 2021/0145819 A1, May 20, 2021
Int. Cl. A61K 38/00 (2006.01); A61K 31/47 (2006.01); A61P 17/02 (2006.01); A61P 17/04 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 38/08 (2019.01); A61K 38/17 (2006.01); A61K 47/10 (2017.01)
CPC A61K 31/47 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0075 (2013.01); A61K 9/06 (2013.01); A61K 38/08 (2013.01); A61K 38/1767 (2013.01); A61K 47/10 (2013.01); A61P 17/02 (2018.01); A61P 17/04 (2018.01)] 19 Claims
 
1. A method of promoting healing or recovery of a hemorrhoid-induced wound of a patient, the method comprising: topically administering a pharmaceutical formulation comprising a therapeutically effective amount of montelukast, or a pharmaceutically acceptable salt of solvate thereof, in admixture with a pharmaceutically-acceptable topical adjuvant, diluent or carrier, directly to a hemorrhoid-induced wound of a patient.